E-LIB Suche - Ergebnisse für: Dupre, Tess V.

1

Neutral ceramidase deficiency protects against cisplatin-in..:

Sears, Sophia M. ; Dupre, Tess V. ; Shah, Parag P....
Journal of Lipid Research. 63 (2022) 3 - p. 100179 , 2022

Link: https://doi.org/10.1016/..

2

Stimulation of 5‐HT1F Receptor Increases Vascular Recovery ..:

Dupre, Tess V. ; Janda, Jaroslav ; Schnellmann, Rick G.
The FASEB Journal. 34 (2020) S1 - p. 1-1 , 2020

Link: https://doi.org/10.1096/..

3

The 5-hydroxytryptamine receptor 1F stimulates mitochondria..:

Dupre, Tess V. ; Jenkins, Dorea P. ; Muise-Helmericks, Robin C..
Biochemical Pharmacology. 169 (2019) - p. 113644 , 2019

Link: https://doi.org/10.1016/..

4

The role of sphingolipids in acute kidney injury:

Dupre, Tess V. ; Siskind, Leah J.
Advances in Biological Regulation. 70 (2018) - p. 31-39 , 2018

Link: https://doi.org/10.1016/..

5

Inhibiting glucosylceramide synthase exacerbates cisplatin-..:

Dupre, Tess V. ; Doll, Mark A. ; Shah, Parag P....
Journal of Lipid Research. 58 (2017) 7 - p. 1439-1452 , 2017

Link: https://doi.org/10.1194/..

6

Common cytotoxic chemotherapeutics induce epithelial-mesenc..:

Shah, Parag P. ; Dupre, Tess V. ; Siskind, Leah J..
Oncotarget. 8 (2017) 14 - p. 22625-22639 , 2017

Link: https://doi.org/10.18632..

7

Targeting of BRAF resistant melanoma via extracellular matr..:

Zeiderman, Matthew R. ; Egger, Michael E. ; Kimbrough, Charles W....
Journal of Surgical Research. 190 (2014) 1 - p. 111-118 , 2014

Link: https://doi.org/10.1016/..

8

Neutral ceramidase deficiency protects against cisplatin-in..:

Sears, Sophia M ; Dupre, Tess V ; Shah, Parag P...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953688/. , 2022

Link: http://www.ncbi.nlm.nih...

9

Moderate aging does not exacerbate cisplatin-induced kidney..:

Sharp, Cierra N ; Doll, Mark ; Dupre, Tess V..
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383196/. , 2019

Link: http://www.ncbi.nlm.nih...

10

Inhibiting glucosylceramide synthase exacerbates cisplatin-..:

Dupre, Tess V ; Doll, Mark A ; Shah, Parag P...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496040/. , 2017

Link: http://www.ncbi.nlm.nih...

11

Repeated administration of low-dose cisplatin in mice induc..:

Sharp, Cierra N ; Doll, Mark A ; Dupre, Tess V...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4796272/. , 2016

Link: http://www.ncbi.nlm.nih...

12

Suramin protects from cisplatin-induced acute kidney injury:

Dupre, Tess V ; Doll, Mark A ; Shah, Parag P...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4877945/. , 2015

Link: http://www.ncbi.nlm.nih...

13

Targeting of BRAF resistant melanoma via extracellular matr..:

Zeiderman, Matthew R ; Egger, Michael E ; Kimbrough, Charles W...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576881/. , 2014

Link: http://www.ncbi.nlm.nih...

14

Neutral ceramidase deficiency protects against cisplatin-in..:

Sophia M. Sears ; Tess V. Dupre ; Parag P. Shah...
http://www.sciencedirect.com/science/article/pii/S0022227522000128. , 2022

Link: https://doi.org/10.1016/..

15

Inhibiting glucosylceramide synthase exacerbates cisplatin-..:

Tess V. Dupre ; Mark A. Doll ; Parag P. Shah...
http://www.sciencedirect.com/science/article/pii/S0022227520335938. , 2017

Link: https://doi.org/10.1194/..